Venetoclax + Azitromycine MFB 7252

Onderbouwend	Stof	Effect	Code
Agarwal SK. Adv Ther 2018;35:2015-23. doi: 10.1007/s12325-018-0793-y.	venetoclax + azitromycine	↓venetoclax Cmax met 25% en AUC met 35%; t1/2 en Tmax vrijwel niet gewijzigd. Regime: venetoclax 100 mg 1-malig op dag 1 van periode 1 en dag 3 van periode 2, azitromycine 500 mg 1x op dag 1 en 250 mg 1dd op dag 2-5; single-center, open-label, nonfasting, two-period study, 12 gezonde vrouwen. Auteurs: the modest changes in venetoclax exposures when given with azithromycin indicate that no dose adjustment would be needed when venetoclax is coadministered with azithromycin or other drugs with P-gp inhibitory potential. The decrease in venetoclax exposures when coadministered with azithromycin was unexpected given that azithromycin is not known to be an inducer of either CYP3A enzymes or P-gp/ other transporters. However, some DDI studies reported a 5–15% decrease in exposures of indinavir, nelfinavir, and trimethoprim/sulfamethoxazole when given with azithromycin.	3A
SPC Venclyxto rev8 23-8-19 en www.ema.europa.eu/en/documents/procedural-steps-after/venclyxto-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf	venetoclax + azitromyicine	getallen als Agarwal 2018	2A

Overig	Stof	Effect
SPC Venclyxto rev8 23-8-19	venetoclax + azitromycine	doseringswijziging venetoclax niet nodig tijdens kortdurig gebruik van azitromycine
Venclexta prod.info USA geraadpleegd 011119 www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf	venetoclax + azitromycine	Avoid concomitant use of moderate P-gp inhibitors (e.g., azithromycin). Consider alternative treatments. If a moderate P-gp inhibitor must be used, reduce the VENCLEXTA dose by at least 50%.

Opmerkingen
PubMed: verder geen hits

Risicofactoren	
Mitigerende factoren	

	Interactie	Actie	Datum
Beslissing WG OncoIA	Ja	Nee	2 december 2020